At a glance
ClinicalIndex Comparison RecordPhase 2Recruiting· 30 target
Drug / intervention
Obecabtagene autoleuceldrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 2 Study Assessing the Clinical Activity and Safety of Obecabtagene Autoleucel as a Consolidation in Patients With Newly Diagnosed High-risk B-cell Acute Lymphocytic Leukemia (ALL)
In Brief
A Phase 2 clinical trial evaluating Obecabtagene autoleucel for Acute Lymphocytic Leukemia (ALL). Currently recruiting, targeting 30 participants across 1 site.
Detailed Summary
The goal of this clinical research study is to learn if obecabtagene autoleucel (obe-cel) can help to control newly diagnosed, high-risk B-cell ALL when given as consolidation therapy. Consolidation therapy is given after the first phase of treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Lymphocytic Leukemia (ALL)
CountriesUnited States
CollaboratorsAutolus, Ltd
Timeline
Phase 2Recruiting
20262027202820292030
First PostedJul 2025
Enrollment StartAug 2025
TodayJul 2026
Primary CompletionMay 2028
Study CompletionMay 2030
First PostedJul 8, 2025
Enrollment StartAug 26, 2025
Primary CompletionMay 31, 2028
Study CompletionMay 31, 2030
TodayJul 1, 2026
Enrollment to primary: 2.8 yearsPosted 12 months agoPrimary completion in 1.9 years
Interventions
Obecabtagene autoleuceldrug
given by Infusion